BioCentury | Jan 18, 2020
Financial News
I-Mab dips in NASDAQ debut, first in years for an innovative Chinese biopharma
...deals for ex-China rights to the candidates. In 2020, U.S. IND submissions are slated for TJ210...
...ligand 13 Hongjiang Li, Staff Writer I-Mab Biopharma Complement receptor 5A (C5AR1) (C5AR) (CD88) Chemokine CXC motif ligand 13 (CXCL13) TJ210 TJX7...
...ligand 13 Hongjiang Li, Staff Writer I-Mab Biopharma Complement receptor 5A (C5AR1) (C5AR) (CD88) Chemokine CXC motif ligand 13 (CXCL13) TJ210 TJX7...
